COMPANY PROFILE // THE 014 REPORT
Faeth Therapeutics, Inc.
FTH (Nasdaq) · Formerly: Sensei Biotherapeutics, Inc.
Assembled from 2 government sources in 4.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber9 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-10-27: a pattern of leadership change.
- Amber8-K Item 3.01 filed: notice of delisting, of a failed continued-listing rule, or of a transfer of listing on 2025-07-09 and 1 more time (last 24 months).
✓ SEC filings✓ State registrationpossible match✗ LEI✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no website, no lobbying registration on record.
Faeth Therapeutics, Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in Austin, TX; listed as FTH (Nasdaq).[source] It has filed 102 documents with the SEC in the last 12 months; the latest is a SCHEDULE 13G, filed 2026-11-17.[source] Its largest institutional holders on 13F filings are MONTANOVA CAPITAL, LLC, Avoro Capital Advisors LLC, BAKER BROS. ADVISORS LP (as of 2026-06-30).[source] Seraphix flags 2 items from these records: 8-K Item 3.01 filed; 9 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-10-27.[source]
- red0
- amber2
- info0
- MONTANOVA CAPITAL, LLC$50.5M
- Avoro Capital Advisors LLC$36.1M
- BAKER BROS. ADVISORS LP$32.2M
- Balyasny Asset Management L.P.$26.1M
- Fairmount Funds Management LLC$18.1M
- Logos Global Management LP$18.1M
- RA CAPITAL MANAGEMENT, L.P.$18.1M
- Vivo Capital, LLC$18.1M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Gerry Christopher · President & PEO (Officer) · latest Form 3 2025-11-24 · filing · LinkedIn search
- Parikh Anand Kiran · Chief Operating Officer (Director,Officer) · latest Form 4 2026-02-19 · filing · LinkedIn search
- Donenberg Phillip B. · Director · latest Form 4 2026-02-17 · filing · LinkedIn search
- Holmen Bob · Director · latest Form 4 2025-05-23 · filing · LinkedIn search
- Humer Kristian · Director · latest Form 4 2025-05-23 · filing · LinkedIn search
- RICKS THOMAS G · Director · latest Form 4 2025-05-23 · filing · LinkedIn search
- RINGO WILLIAM R · Director · latest Form 4 2025-05-23 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Madison A. Jones Madison A. Jones Cooley LLP · Exhibit 5.1 legal opinion, S-8 filed 2026-11-03
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001829802 | source |
| EIN | 00-0000000 | source |
| Connecticut business ID | 1381433 | record |
| Business address (SEC) | 701 TILLERY STREET #12 #1010, AUSTIN, TX, 78702 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; <br>Emerging growth company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; <br>Emerging growth company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
ADDRESS · ZIP CODE
Location context
At the same address (8)
- OPERATION FISTULA · IRS-registered organization
- TDLR SOCIAL CLUB · IRS-registered organization
- XTEXAS TRAIL ASSOCIATION · IRS-registered organization
- THE PEOPLE SANCTUARY · IRS-registered organization
- DEGREE PARTNERS · IRS-registered organization
- ALLGO · IRS-registered organization
- CARBON TRACKER INITIATIVE INC · IRS-registered organization
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Tectonic Therapeutic, Inc. · Donenberg Phillip B.
- Taysha Gene Therapies, Inc. · Donenberg Phillip B.
- 4D Molecular Therapeutics, Inc. · Humer Kristian
- Foghorn Therapeutics Inc. · Humer Kristian
- Ovintiv Inc. · RICKS THOMAS G
- ASSEMBLY BIOSCIENCES, INC. · RINGO WILLIAM R
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-09 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-11-09 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-11-03 filing S-8 · SEC EDGAR
- 2026-11-03 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-11-03 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-10-27 officer change 8-K items 5.02 · SEC EDGAR
- 2026-09-17 officer change 8-K items 5.02 · SEC EDGAR
- 2026-08-11 filing 144 · SEC EDGAR
- 2026-08-04 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-04 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-07-23 officer change 8-K items 5.02 · SEC EDGAR
- 2026-06-18 filing 8-K items 1.01,8.01,9.01 · SEC EDGAR
- 2026-06-18 filing S-3ASR · SEC EDGAR
- 2026-06-16 name change Name changed from Sensei Biotherapeutics, Inc. · SEC EDGAR
- 2026-06-15 officer change 8-K items 1.02,5.02,5.03,7.01,8.01,9.01 · SEC EDGAR
- 2026-06-12 filing EFFECT · SEC EDGAR
- 2026-06-10 filing CORRESP · SEC EDGAR
- 2026-06-10 filing S-3/A · SEC EDGAR
- 2026-06-10 officer change 8-K items 5.02,5.03,5.07,9.01 · SEC EDGAR
- 2026-06-02 filing 10-K/A · SEC EDGAR
- 2026-06-02 filing CORRESP · SEC EDGAR
- 2026-06-02 filing S-3/A · SEC EDGAR
- 2026-05-28 filing UPLOAD · SEC EDGAR
- 2026-05-22 filing DEFA14A · SEC EDGAR
- 2026-05-22 filing 8-K items 8.01 · SEC EDGAR
- 2026-05-21 filing DEFA14A · SEC EDGAR
- 2026-05-21 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-05-15 filing S-8 · SEC EDGAR
- 2026-05-15 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-15 filing 8-K items 2.02,9.01 · SEC EDGAR
155 earlier entries
- 2026-04-29 filing 144
- 2026-04-28 filing S-3
- 2026-04-27 filing ARS
- 2026-04-27 filing DEFA14A
- 2026-04-27 filing Proxy statement
- 2026-04-16 officer change 8-K items 5.02
- 2026-04-16 filing PRE 14A
- 2026-04-15 filing 8-K/A items 9.01
- 2026-03-30 filing Annual report (10-K)
- 2026-03-30 filing 8-K items 2.02,9.01
- 2026-03-04 filing D
- 2026-02-24 filing 144
- 2026-02-19 insider First Form 3/4/5 on record for Parikh Anand Kiran (Chief Operating Officer)
- 2026-02-18 filing 144
- 2026-02-18 officer change 8-K items 1.01,2.01,3.02,5.02,5.03,7.01,9.01
- 2026-02-17 insider First Form 3/4/5 on record for Donenberg Phillip B. (Director)
- 2026-02-13 officer change 8-K items 5.02
- 2026-01-27 filing 144
- 2025-12-23 officer change 8-K items 5.02
- 2025-12-09 filing 144
- 2025-12-04 filing 144
- 2025-12-04 filing 144
- 2025-11-24 insider First Form 3/4/5 on record for Gerry Christopher (President & PEO)
- 2025-11-14 filing Quarterly report (10-Q)
- 2025-11-14 filing 8-K items 2.02,9.01
- 2025-10-30 filing 8-K items 7.01,9.01
- 2025-10-17 filing 8-K items 7.01,9.01
- 2025-08-05 filing Quarterly report (10-Q)
- 2025-08-05 filing 8-K items 2.02,9.01
- 2025-07-09 filing 8-K items 3.01
- 2025-06-13 filing 8-K items 5.03,9.01
- 2025-05-23 filing 8-K items 5.07
- 2025-05-23 insider First Form 3/4/5 on record for Holmen Bob (Director)
- 2025-05-23 insider First Form 3/4/5 on record for Humer Kristian (Director)
- 2025-05-23 insider First Form 3/4/5 on record for RICKS THOMAS G (Director)
- 2025-05-23 insider First Form 3/4/5 on record for RINGO WILLIAM R (Director)
- 2025-05-06 filing Quarterly report (10-Q)
- 2025-05-06 filing 8-K items 2.02,9.01
- 2025-04-11 filing ARS
- 2025-04-11 filing DEFA14A
- 2025-04-11 filing Proxy statement
- 2025-04-01 filing PRE 14A
- 2025-03-28 filing S-8
- 2025-03-28 filing Annual report (10-K)
- 2025-03-28 filing 8-K items 2.02,9.01
- 2025-03-27 filing 8-K items 7.01,9.01
- 2025-01-07 filing 8-K items 3.01,9.01
- 2024-11-14 filing Quarterly report (10-Q)
- 2024-11-14 filing 8-K items 2.02,9.01
- 2024-10-30 officer change 8-K items 5.02
- 2024-09-20 officer change 8-K items 5.02
- 2024-08-06 filing Quarterly report (10-Q)
- 2024-08-06 filing 8-K items 2.02,9.01
- 2024-07-12 filing 8-K items 3.01
- 2024-06-27 officer change 8-K items 5.02
- 2024-06-13 filing 8-K items 5.07
- 2024-06-03 filing 8-K items 7.01,9.01
- 2024-05-23 filing 8-K items 7.01,9.01
- 2024-05-09 filing Quarterly report (10-Q)
- 2024-05-09 filing 8-K items 2.02,9.01
- 2024-04-29 filing ARS
- 2024-04-29 filing DEFA14A
- 2024-04-29 filing Proxy statement
- 2024-04-12 officer change 8-K items 5.02
- 2024-04-02 officer change 8-K items 5.02
- 2024-03-07 filing SC 13D/A
- 2024-03-05 filing 8-K items 1.01,3.03,9.01
- 2024-02-29 filing S-8
- 2024-02-29 filing Annual report (10-K)
- 2024-02-28 filing 8-K items 2.02,9.01
- 2024-02-13 filing SC 13D/A
- 2024-02-08 officer change 8-K items 5.02,8.01
- 2024-01-04 filing 8-K items 7.01,9.01
- 2023-11-07 filing Quarterly report (10-Q)
- 2023-11-07 filing 8-K items 2.02,9.01
- 2023-11-06 filing 8-K items 7.01
- 2023-11-03 filing SC 13D
- 2023-11-03 filing 8-K items 7.01,9.01
- 2023-10-20 filing 8-K items 3.01
- 2023-08-17 filing 424B5
- 2023-08-03 filing Quarterly report (10-Q)
- 2023-08-03 filing 8-K items 2.02,9.01
- 2023-07-10 filing 8-K items 5.07
- 2023-06-27 filing 8-K items 7.01,9.01
- 2023-06-23 filing 8-K items 1.01,3.03,9.01
- 2023-06-15 filing ARS
- 2023-06-15 filing Proxy statement
- 2023-06-02 filing SC 13D/A
- 2023-05-23 filing SC 13D/A
- 2023-05-23 filing DEFA14A
- 2023-05-23 filing 8-K items 1.01,9.01
- 2023-05-09 filing Quarterly report (10-Q)
- 2023-05-09 filing 8-K items 2.02,9.01
- 2023-05-01 filing 10-K/A
- 2023-04-20 filing 8-K items 7.01,9.01
- 2023-03-29 filing S-8
- 2023-03-29 filing Annual report (10-K)
- 2023-03-28 filing 8-K items 2.02,9.01
- 2023-03-13 filing 8-K items 7.01,9.01
- 2023-03-10 filing DEFA14A
- 2023-03-10 filing 8-K items 8.01,9.01
- 2023-03-09 filing SC 13D/A
- 2023-03-07 filing 8-K items 1.01,3.03,5.03,7.01,9.01
- 2023-03-07 filing 8-A12B
- 2023-02-06 officer change 8-K items 5.02,7.01,9.01
- 2022-12-09 filing 8-K items 5.03,9.01
- 2022-12-08 officer change 8-K items 2.05,5.02,7.01,9.01
- 2022-11-21 filing SC 13D/A
- 2022-11-10 filing 8-K items 7.01,9.01
- 2022-11-08 filing Quarterly report (10-Q)
- 2022-11-08 filing 8-K items 2.02,7.01,9.01
- 2022-11-02 filing SC 13D/A
- 2022-09-30 filing 8-K items 7.01,9.01
- 2022-08-31 filing 8-K items 7.01,9.01
- 2022-08-09 filing Quarterly report (10-Q)
- 2022-08-09 filing 8-K items 2.02,7.01,9.01
- 2022-08-01 filing 3/A
- 2022-07-19 filing SC 13D
- 2022-06-14 filing 8-K items 5.07
- 2022-05-10 filing Quarterly report (10-Q)
- 2022-05-10 filing S-8
- 2022-05-10 filing 8-K items 2.02,9.01
- 2022-05-09 filing EFFECT
- 2022-05-09 filing 424B5
- 2022-05-09 filing S-3/A
- 2022-05-06 filing CORRESP
- 2022-05-06 filing CORRESP
- 2022-05-04 filing CORRESP
- 2022-04-28 filing DEFA14A
- 2022-04-28 filing DEFA14A
- 2022-04-28 filing Proxy statement
- 2022-04-20 filing 8-K items 7.01,9.01
- 2022-03-22 filing UPLOAD
- 2022-03-15 filing S-3
- 2022-03-15 filing Annual report (10-K)
- 2022-03-10 filing 8-K items 2.02,9.01
- 2022-03-09 officer change 8-K items 5.02,7.01,9.01
- 2022-01-10 filing 8-K items 7.01,9.01
- 2021-12-06 filing 8-K items 7.01,9.01
- 2021-11-16 filing 8-K items 7.01,9.01
- 2021-11-10 filing Quarterly report (10-Q)
- 2021-11-09 filing 8-K items 2.02,9.01
- 2021-09-08 filing 8-K items 7.01,9.01
- 2021-08-11 filing Quarterly report (10-Q)
- 2021-08-10 filing 3/A
- 2021-08-04 filing 8-K items 2.02,9.01
- 2021-08-02 officer change 8-K items 5.02
- 2021-06-28 filing 8-K items 7.01,9.01
- 2021-06-17 officer change 8-K items 5.02
- 2021-05-13 filing Quarterly report (10-Q)
- 2021-05-12 filing 8-K items 2.02,9.01
- 2021-05-03 officer change 8-K items 5.02,9.01
- 2021-04-05 officer change 8-K items 5.02,7.01,9.01
- 2021-03-30 filing Annual report (10-K)
- 2021-03-25 filing 8-K items 2.02,9.01
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-09 (within 30 days) 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-11-09 (within 30 days) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-11-03 (within 30 days) S-8 filed
- 2026-11-03 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-11-03 (within 30 days) 10-Q filed
- 2026-10-27 (within 30 days) 8-K filed: Item 5.02 officer or director change
- 2026-09-17 (older) 8-K filed: Item 5.02 officer or director change
- 2026-08-04 (older) 10-Q filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:FTH The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
2 possible matches held apart, matched by name only, not counted above; 1 record under a former name, shown apart.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1829802 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | FTH / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| CUSIP | 81728A207 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001829802 | SEC EDGAR |
former name (shown apart, not merged) (1)
- former nameSensei Biotherapeutics, Inc. · ClinicalTrials.gov
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Net income (loss) (fiscal year ended 2025-12-31) | -$21,085,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 10:23 UTC | Report an error |
| Total assets (at 2025-12-31) | $22,902,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 10:23 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $18,592,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 10:23 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $8,668,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-20 10:23 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
| State of incorporation | DE | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
| Business address | 701 TILLERY STREET #12 #1010, AUSTIN, TX, 78702 | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$20,453,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 10:23 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $16,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-20 10:23 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $1,429,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-20 10:23 UTC | Report an error |
| Form D total offering amount (D filed 2026-03-04) | $348,906,500 | 2026-03-04 | D | as filed | 2026-11-20 10:23 UTC | Report an error |
| Form D total amount sold (D filed 2026-03-04) | $348,906,500 | 2026-03-04 | D | as filed | 2026-11-20 10:23 UTC | Report an error |
| Form D industry group | Biotechnology | 2026-03-04 | D | as filed | 2026-11-20 10:23 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2026-03-04 | D | as filed | 2026-11-20 10:23 UTC | Report an error |
| Form D date of first sale | 2026-02-17 | 2026-03-04 | D | as filed | 2026-11-20 10:23 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-03 · accession 0001193125-26-444376
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$20,398,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-03 | 0001193125-26-444376 | 2026-11-20 10:23 UTC | Report an error |
| Cash and cash equivalents | $14,180,000 | at 2026-09-30 | 10-Q | 2026-11-03 | 0001193125-26-444376 | 2026-11-20 10:23 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-09 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-11-09 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-11-03 Filing S-8 filed
- 2026-11-03 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-11-03 Filing 10-Q filed
- 2026-10-27 Filing 8-K filed: Item 5.02 officer or director change
- 2026-09-17 Filing 8-K filed: Item 5.02 officer or director change
- 2026-08-04 Filing 10-Q filed
- 2026-08-04 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-23 Filing 8-K filed: Item 5.02 officer or director change
- 2026-06-18 Filing 8-K filed: Item 1.01 material agreement; Item 8.01 other event; Item 9.01 exhibits
- 2026-06-18 Filing S-3ASR filed
- 2026-06-15 Filing 8-K filed: Item 1.02 agreement terminated; Item 5.02 officer or director change; Item 5.03 charter or bylaw amendment; Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-06-12 Filing EFFECT filed
- 2026-06-10 Filing CORRESP filed
- 2026-06-10 Filing S-3/A filed
- 2026-06-10 Filing 8-K filed: Item 5.02 officer or director change; Item 5.03 charter or bylaw amendment; Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-06-02 Filing 10-K/A filed
- 2026-06-02 Filing CORRESP filed
- 2026-06-02 Filing S-3/A filed
- 2026-05-28 Filing UPLOAD filed
- 2026-05-22 Filing DEFA14A filed
- 2026-05-22 Filing 8-K filed: Item 8.01 other event
- 2026-05-21 Filing DEFA14A filed
- 2026-05-21 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | MONTANOVA CAPITAL, LLC | $50,502,575 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 2 | Avoro Capital Advisors LLC | $36,100,975 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 3 | BAKER BROS. ADVISORS LP | $32,160,275 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 4 | Balyasny Asset Management L.P. | $26,054,950 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 5 | Fairmount Funds Management LLC | $18,050,500 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 6 | Logos Global Management LP | $18,050,500 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 7 | RA CAPITAL MANAGEMENT, L.P. | $18,050,500 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 8 | Vivo Capital, LLC | $18,050,500 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 9 | Caligan Partners LP | $15,736,675 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 10 | B Group, Inc. | $15,254,225 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
2 state and city records carry this company's exact name, from 2 sources. Possible matches only.
Connecticut business registrations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchFaeth Therapeutics, Inc. · exact legal name · sx:ctsos:1381433 Compare
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchFaeth Therapeutics · exact name match to 'Faeth Therapeutics, Inc.' (no other entity shares the name) · sx:ctgov:h4689ff5d60018f21 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1829802.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001829802. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.